Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway

Journal of Pathology

Volumn 236, Issue 4, 2015, Pages 407-420

  Lavoz, Carolina ^a   Alique, Matilde ^a   Rodrigues Diez, Raquel ^a   Pato, Janos ^b   Keri, Gyorgy ^b,c   Mezzano, Sergio ^d   Egido, Jesús ^a   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Vichem Chemie Ltd   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

gremlin; inflammation; NF B; VEGFR2

Indexed keywords

CYSTEINE; GREMLIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; AUTACOID; CKTSF1B1 PROTEIN, MOUSE; GREM1 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VEGFR2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; CROSS LINKING; FEMALE; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY CELL; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; KIDNEY; MALE; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; URETER OBSTRUCTION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MICE, INBRED C57BL; NEPHRITIS; NF-KAPPA B; PROTEIN BINDING; RETROSPECTIVE STUDIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; URETERAL OBSTRUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84937522942     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4537     Document Type: Article

References (53)

1. Topol LZ, Bardot B, Zhang Q, et al., Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. J Biol Chem 2000; 275: 8785-8793.
2. Michos O, Panman L, Vintersten K, et al., Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 2004; 131: 3401-3410.
3. Merino R, Rodriguez-Leon J, Macias D, et al., The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 1999; 126: 5515-5522.
4. Hsu DR, Economides AN, Wang X, et al., The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1998; 1: 673-683.
5. Boers W, Aarrass S, Linthorst C, et al., Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem 2006; 281: 16289-16295.
6. Namkoong H, Shin SM, Kim HK, et al., The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 2006; 6: 74.
7. Zode GS, Clark AF, Wordinger RJ,. Bone morphogenetic protein 4 inhibits TGF-β2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia 2009; 57: 755-766.
8. Costello CM, Cahill E, Martin F, et al., Role of gremlin in the lung: development and disease. Am J Respir Cell Mol Biol 2010; 42: 517-523.
9. Farkas L, Farkas D, Gauldie J, et al., Transient overexpression of Gremlin results in epithelial activation and reversible fibrosis in rat lungs. Am J Respir Cell Mol Biol 2011; 44: 870-878.
10. Stabile H, Mitola S, Moroni E, et al., Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 2007; 109: 1834-1840.
11. Kim M, Yoon S, Lee S, et al., Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PLoS One 2012; 7:e35100.
12. Mitola S, Ravelli C, Moroni E, et al., Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010; 116: 3677-3680.
13. Corsini M, Moroni E, Ravelli C, et al., Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. Arterioscler Thromb Vasc Biol 2014; 34: 136-145.
14. Olsson AK, Dimberg A, Kreuger J, et al., VEGF receptor signalling-in control of vascular function. Nature Rev Mol Cell Biol 2006; 7: 359-371.
15. Chiodelli P, Mitola S, Ravelli C, et al., Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 2011; 31: e116-127.
16. Maiolo D, Mitola S, Leali D, et al., Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation. J Am Chem Soc 2012; 134: 14573-14579.
17. Mezzano S, Droguett A, Burgos ME, et al., Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1882-1890.
18. Carvajal G, Droguett A, Burgos ME, et al., Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 2008; 40: 734-739.
19. McMahon R, Murphy M, Clarkson M, et al., IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-β1. J Biol Chem 2000; 275: 9901-9904.
20. Lappin DW, McMahon R, Murphy M, et al., Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy. Nephrol Dial Transplant 2002; 17 (Suppl 9): 65-67.
21. Dolan V, Murphy M, Sadlier D, et al., Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 1034-1039.
22. Droguett A, Krall P, Burgos ME, et al., Tubular overexpression of gremlin induces renal damage susceptibility in mice. PLoS One 2014; 9:e101879.
23. Roxburgh SA, Kattla JJ, Curran SP, et al., Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 2009; 58: 1641-1650.
24. Zhang Q, Shi Y, Wada J, et al., In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 2010; 5:e11709.
25. Rodrigues-Diez R, Lavoz C, Carvajal G, et al., Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. Nephron Exp Nephrol 2012; 122: 62-74.
26. Li G, Li Y, Liu S, et al., Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway. J Cell Biochem 2013; 114: 2101-2113.
27. Lai LW, Moeckel GW, Lien YH,. Kidney-targeted liposome-mediated gene transfer in mice. Gene Ther 1997; 4: 426-431.
28. Fong TA, Shawver LK, Sun L, et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
29. Esteban V, Lorenzo O, Rupérez M, et al., Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-1529.
30. Lõpez-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, et al., Parthenolide modulates the NF-κB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1864-1870.
31. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, et al., TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol 2013; 231: 480-494.
32. Ardura JA, Rayego-Mateos S, Rámila D, et al,. Parathyroid hormone-related protein promotes epithelial-mesenchymal transition. J Am Soc Nephrol 2010; 21: 237-248.
33. Humphreys BD, Xu F, Sabbisetti V, et al., Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123: 4023-4035.
34. Parikh CR, Devarajan P,. New biomarkers of acute kidney injury. Crit Care Med 2008; 36: S159-S165.
35. Devarajan P., Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest 2008; 241: 89-94.
36. Moreno JA, Moreno S, Rubio-Navarro A, et al., Targeting chemokines in proteinuria-induced renal disease. Expert Opin Ther Targets 2012; 16: 833-845.
37. Sanz AB, Sanchez-Niño MD, Ramos AM, et al., NF-κB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
38. Cui R, Tieu B, Recinos A, et al., RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor κB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res 2006; 99: 723-730.
39. Klahr S, Morrissey J,. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283: F861-F875.
40. Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz C, et al., Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. Biomed Res Int 2014; 2014: 802841.
41. Chen B, Blair DG, Plisov S, et al., Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J Immunol 2004; 173: 5914-5917.
42. -/- mice. J Biol Chem 2013; 288: 31635-31645.
43. Simões Sato AY, Bub GL, Campos AH,. BMP-2 and -4 produced by vascular smooth muscle cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation. Atherosclerosis 2014; 235: 45-55.
44. Kane R, Stevenson L, Godson C, et al., Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. Br J Ophthalmol 2005; 89: 1638-1642.
45. Huang H, Huang H, Li Y, et al., Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. BMC Nephrol 2013; 14: 33.
46. Mezzano S, Aros C, Droguett A, et al., NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-2512.
47. Mayer G., Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011; 26: 1132-1137.
48. Schrijvers BF, De Vriese AS, Tilton RG, et al., Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005; 37: 21-25.
49. Sung SH, Ziyadeh FN, Wang A, et al., Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104.
50. Schrijvers BF, Flyvbjerg A, Tilton RG, et al., A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324-329.
51. Ku CH, White KE, Dei Cas A, et al., Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833.
52. Lin SL, Chang FC, Schrimpf C, et al., Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011; 178: 911-923.
53. Sun D, Bu L, Liu C, et al., Therapeutic effects of human amniotic fluid-derived stem cells on renal interstitial fibrosis in a murine model of unilateral ureteral obstruction. PLoS One 2013; 8:e65042.